Legal Representation
Attorney
Anne H. Peck
USPTO Deadlines
Application History
10 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 31, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| Mar 31, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Mar 31, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Dec 14, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 14, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 14, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 12, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 13, 2022 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Apr 12, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Apr 12, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, all for in-vivo laboratory use in gene therapy
First Use Anywhere:
0
First Use in Commerce:
0
Class 005
Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, inflammatory, autoimmune, musculoskeletal, ophthalmologic, respiratory, and hematologic diseases and disorders
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
Biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assays
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disorders
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the word "ultragenyx" in lower case letters above the words "gene therapy". The formative "ultra" and the words "gene therapy" are purple and the formative "genyx" is green. The letter "x" in "genyx" is stylized and features an enlongated stroke reaching above and below the word "ultragenyx". A gray hexagon is below the formative "ultra" and to the left of the words "gene therapy." A double helix, one strand of which is purple and one strand of which is green, is vertically oriented inside the gray hexagon.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
001
005
042
044